NASDAQ:CPIX

Cumberland Pharmaceuticals. Stock News

Healthcare > Drug Manufacturers - Specialty & Generic

Invest in CPIX

$5.24

-0.620 (-10.58%)

At Close: Jun 13, 2025

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

04:05pm, Tuesday, 27'th May 2025

Analysis Shows 23% Reduction in Morphine Use with Favorable Safety Profile in Patients 60 Years of Age and Older NASHVILLE, Tenn. , May 27, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

04:05pm, Tuesday, 13'th May 2025

Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial NASHVILLE, Tenn. and CAMBRIDGE, England , May 13, 2025 /PRNewswire/ -- Cumberland Phar

Cumberland Pharmaceuticals, Inc. (CPIX) Q1 2025 Earnings Call Transcript

04:23am, Saturday, 10'th May 2025

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX ) Q1 2025 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - CEO Todd Anth

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

04:05pm, Tuesday, 06'th May 2025

NASHVILLE, Tenn. , May 6, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands del

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

04:05pm, Tuesday, 29'th Apr 2025

NASHVILLE, Tenn. , April 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 financ

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

04:05pm, Wednesday, 19'th Mar 2025

Ifetroban demonstrated significant 5.4% improvement in cardiac function NASHVILLE, Tenn. , March 19, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical co

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript

07:14pm, Tuesday, 04'th Mar 2025

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Molly Aggas – Account Supervisor-Dalton Agency A.J. Kazimi – Chief Exe

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

04:05pm, Tuesday, 04'th Mar 2025

2024 highlights include expanded product labeling, key FDA designations and new study publications Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval NASHV

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

04:05pm, Tuesday, 25'th Feb 2025

NASHVILLE, Tenn. , Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial res

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

07:30am, Tuesday, 18'th Feb 2025

Vibativ® is a life-saving antibiotic for pneumonia and serious skin infections Approval in China paves the way for launch in world's second-largest market NASHVILLE, Tenn. and SHANGHAI , Feb. 18, 202

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

01:31pm, Tuesday, 04'th Feb 2025

On Tuesday, Cumberland Pharmaceuticals Inc. CPIX released topline results from its Phase 2 FIGHT DMD trial.

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

07:30am, Tuesday, 04'th Feb 2025

NASHVILLE, Tenn. , Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases,

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by